
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72938
10.1038/s41598-024-72938-3
Article
Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids
Ohta Tsuyoshi oota-t@med.id.yamagata-u.ac.jp

1
Sugimoto Masahiro 2
Ito Yasufumi 1
Horikawa Shota 1
Okui Yosuke 1
Sakaki Hirotsugu 1
Seino Manabu 1
Sunamura Makoto 3
Nagase Satoru 1
1 https://ror.org/00xy44n04 grid.268394.2 0000 0001 0674 7277 Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, 990-9585 Japan
2 https://ror.org/02kn6nx58 grid.26091.3c 0000 0004 1936 9959 Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052 Japan
3 https://ror.org/00k5j5c86 grid.410793.8 0000 0001 0663 3325 Department of Intestinal Surgery Medical Center, Tokyo Medical University, Hachioji, Tokyo 193-0998 Japan
16 9 2024
16 9 2024
2024
14 2155525 1 2024
11 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Ovarian cancer (OC) is the most lethal gynecologic cancer, mainly due to late diagnosis with widespread peritoneal spread at first presentation. We performed metabolomic analyses of ovarian and paired control tissues using capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry to understand its metabolomic dysregulation. Of the 130 quantified metabolites, 96 metabolites of glycometabolism, including glycolysis, tricarboxylic acid cycles, urea cycles, and one-carbon metabolites, showed significant differences between the samples. To evaluate the local and systemic metabolomic differences in OC, we also analyzed low or non-invasively available biofluids, including plasma, urine, and saliva collected from patients with OC and benign gynecological diseases. All biofluids and tissue samples showed consistently elevated concentrations of N1,N12-diacetylspermine compared to controls. Four metabolites, polyamines, and betaine, were significantly and consistently elevated in both plasma and tissue samples. These data indicate that plasma metabolic dysregulation, which the most reflected by those of OC tissues. Our metabolomic profiles contribute to our understanding of metabolomic abnormalities in OC and their effects on biofluids.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72938-3.

Keywords

Ovarian cancer
Metabolomic dysfunction
Cancer tissues
Normal tissue
Biofluids
Subject terms

Cancer
Cancer metabolism
Gynaecological cancer
http://dx.doi.org/10.13039/501100001691 Japan Society for the Promotion of Science 21K09509 21K09532 Ohta Tsuyoshi Nagase Satoru issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Metabolomic reprogramming of cancer cells is cancer hallmarks and is acquired during its multistep development1. Metabolomic alterations such as increased rates of glycolysis, glutaminolysis and lipid synthesis in cancer provide a foundation for sustained tumor growth2. Metabolites are the end products of the complex effects of the actions of genes, proteins, and enzymes, as well as environmental exposure, and they reflect the disease phenotype3,4. Metabolomics can provide measurements of large numbers of metabolites in cells, tissues or biological fluids, and is used in studies including targeted analysis, metabolomic profiling, and fingerprinting5,6.

Ovarian cancer (OC) is the most lethal gynecological cancer, mainly due to late diagnosis accompanied by widespread peritoneal dissemination at first presentation. The 5-year survival rate of patients with distant metastases and disease localized to the ovary is 31.5% and 92.4%, respectively7; therefore, early diagnosis is crucial to improve patient prognosis. CA-125 and transvaginal sonography (TVS) are commonly used for OC screening. However, a meta-analysis of clinical trials showed that screening for CA-125 and/or TVS did not decrease OC mortality8. Recently, metabolomics has been used to identify new biomarkers and investigate the pathogenesis of OC. Mass spectrometric metabolomic profiling of plasma in combination with CA-125 allows early detection of OC with high sensitivity9. Metabolomic profiling of 448 plasma samples related to OC identified piperine, 3-indolepropionic acid, 5-hydroxyindoleacetaldehyde, and hydroxyphenyllactate as OC metabolic biomarkers10. These metabolites could distinguish OC from benign ovarian tumors and uterine fibroids, and early-stage disease from late-stage disease. Another study using metabolomics of plasma, ascites and tumor tissues showed that low serum phospholipids and essential amino acids were predictors of worse survival in OC11. These findings suggest that exploring the metabolic characteristics of biological samples could facilitate early diagnosis and aid in understanding the underlying biological mechanisms of OC. Several previous studies focusing on metabolomic profiling for OC have evaluated blood9,10,12, urine13,14, and tissue15–17 separately as biological samples. Currently, salivary metabolomics is a well-established, novel, and non-invasive biological sampling technique. It has been used to distinguish patients with breast, pancreatic, and oral cancer18–20. However, whether metabolomic changes in tumors correlate with measurable changes in metabolites in the blood, urine, and saliva remains unknown.

This study aimed to evaluate the local and systemic metabolomic differences in OC using targeted metabolomics of tumor tissues, preoperative plasma, urine, and saliva, and to identify the best biofluid associated with metabolic changes in tumors.

Results

Patient characteristics

Table 1 presents the participant characteristics, including 37 patients with ovarian cancer (OC) and 30 patients with benign gynecological diseases, defined as controls (C). The median ages of the OC and C groups were 52 (33–86) and 43 (25–71), respectively. The two groups had no significant difference in median body mass index (BMI). No significant difference was observed in the proportion of diabetes, hyperlipidemia, and smokers between the two groups. The sample numbers of International Federation of Gynecology and Obstetrics (FIGO) I, II, III, and IV were 20, seven, nine and one, respectively. The histological types of OC included nine high-grade serous carcinomas, 10 endometrioid carcinomas, 14 clear cell carcinomas, two mucinous carcinomas, one carcinosarcoma, and one small cell carcinoma. The C group consisted of eight benign ovarian tumors, 19 uterine myomas, one adenomyosis, one poly cystic ovary syndrome (PCOS), and one sterility.

Table 1 Characteristics of subjects.

	Ovarian cancer	Control	p-value	
Number of patients	37	30		
Age (median, range)	52 (33–86)	43 (25–71)	< 0.0001	
BMI (median, range)	22.2 (18.5–34.1)	22.15 (19.4–35)	0.421	
Diabetes	1 (2.7%)	1 (3.3%)	1	
Hyperlipidemia	6 (16.2%)	2 (6.6%)	0.281	
Smoking habit	4 (10.8%)	7 (23.3%)	0.199	
Stage				
I	20 (54.0%)			
II	7 (18.9%)			
III	9 (24.3%)			
IV	1 (2.7%)			
Histological type				
High grade serous carcinoma	9 (24.3%)			
Endometrioid carcinoma	10 (27.0%)			
Clear cell carcinoma	14 (37.8%)			
Mucinous carcinoma	2 (5.4%)			
Carcinosarcoma	1 (2.7%)			
Small cell carcinoma	1 (2.7%)			
Disease				
Ovarian tumor (benign)		8 (26.6%)		
Uterine myoma		19 (63.3%)		
Adenomyosis		1 (3.3%)		
PCOS		1 (3.3%)		
Sterility		1 (3.3%)		

Metabolic profile of ovarian cancer and normal tissues

Of the OC samples (n = 37), 24 paired ovarian tumor (OT) and normal tissues (NT) were used for subsequent analyses. Metabolomic analyses quantified 130 metabolites in the tissue samples. In totally, 96 metabolites significantly different between the OT and NT groups (Fig. 1A). Most of the metabolites showed higher concentrations in the OT group, including N1,N12-diacetylspermine, UDP-N-acetylglucosamine, and adenosine monophosphate (AMP), whearas only nine metabolites showed lower concentrations, such as phosphoenolpyruvate (PEP). The heat map shows the metabolomic profiles of the individual samples (Fig. 1B).

Fig. 1 Metabolomic profile of paired tumor (T) and normal (N) tissues. (A) Volcano plot of metabolite concentrations (µmol/g). X-axis indicates the log2-fold change (FC) of the averaged values of (T/N). Y-axis indicates the –log10(P-value) (Wilcoxon test corrected by FDR). Metabolites showing Y > 1.3, i.e., P < 0.05, were colored red or blue. Resentative metabolites were shown in box plots. (B) Heatmap of each metabolite’s higher (red) and lower (blue) concentration. Normalization by the sum, log transformation, and auto-scaling were used as options for data processing. Elucidation distance was used for clustering. (C) Pathway analysis. No normalization was used for data processing. X and Y-axes indicate the pathway impact and –log10(P-value). Ten representative pathways were labeled. (1) Pyruvate metabolism. (2) Glycolysis / Gluconeogenesis. (3) Propanoate metabolism. (4) Amino sugar and nucleotide sugar metabolism. (5) Citrate cycle (TCA cycle). (6) Glycine, serine and threonine metabolism. (7) Pentose and glucuronate interconversions. (8) Primary bile acid biosynthesis. (9) Cysteine and methionine metabolism. (10) Selenocompound metabolism.

Multivariate analyses also revealed apparent profile-level differences between the OT and NT groups. The score and loading plots of the PCA are illustrated in Figure S1A and S1B, respectively. Score plots of PLS-DA and variable importance of prediction (VIP) scores are also shown in Figure S1C and S1D, respectively. For example, guanosine monophosphate (GMP) contributed the most to the separation according to the VIP score. The histological subtype and clinical stage had no apparent profile-level difference (Figures S2).

The pathway analysis revealed pathway-level differences between the two groups (Fig. 1C). The significantly different pathways included glucose and amino acids metabolism, such as (1) pyruvate metabolism, (2) glycolysis/gluconeogenesis, (3) propanoate metabolism, (4) amino sugar and nucleotide sugar metabolism, (5) citrate cycle (TCA cycle), and (6) glycine, serine and threonine metabolism (Table 2). Individual data, including glucose metabolism and related pathways, were visualized in a pathway form (Fig. 2). Except for the two intermediate metabolites in glycolysis, most metabolites showed higher concentrations in the OT group.

Table 2 Pathway ranking for tissue.

Rank	Pathway	Number of total compounds	Hits	Raw
p-value	-LOG10
p-value	Holm adjust	FDR	Impact	
1	Pyruvate metabolism	22	4	4.13E-13	12.384	2.02E-11	1.01E-11	0.0311	
2	Glycolysis / Gluconeogenesis	26	5	4.13E-13	12.384	2.02E-11	1.01E-11	0.14972	
3	Propanoate metabolism	23	3	3.81E-12	11.419	1.79E-10	6.22E-11	0	
4	Amino sugar and nucleotide sugar metabolism	37	10	1.23E-10	9.9118	5.64E-09	1.50E-09	0.32396	
5	Citrate cycle

(TCA cycle)

	20	5	6.63E-10	9.1787	2.98E-08	6.49E-09	0.19704	
6	Glycine, serine and threonine metabolism	33	9	1.03E-09	8.9874	4.53E-08	8.41E-09	0.54222	
7	Pentose and glucuronate interconversions	18	4	2.60E-09	8.585	1.12E-07	1.82E-08	0.20312	
8	Primary bile acid biosynthesis	46	1	9.29E-09	8.0319	3.90E-07	5.69E-08	0.00758	
9	Cysteine and methionine metabolism	33	8	1.31E-08	7.8821	5.38E-07	7.14E-08	0.34331	
10	Selenocompound metabolism	20	1	1.88E-08	7.7252	7.53E-07	9.23E-08	0	
FDR, false discovery rate.

Fig. 2 Pathway visualization of metabolomic concentrations in paired ovarian tumor (OT) and normal tissues (NT). Individual data were visualized in dot plots. The left and right plots are the data of NT and OT. The metabolites showing P < 0.05 (Wilcoxon test corrected by FDR) were colored pink (higher in OT) and light blue (lower in OT). The Y-axis indicates the metabolite concentration (µmol/g).

Metabolic profile of biofluid samples

Plasma sample analyses quantified 84 metabolites and revealed that seven metabolites differed significantly between OC and C groups (Fig. 3A). For example, betaine and N1,N12-diacetylspermine had higher concentrations in the OC, whereas 4-methyl-2-oxopentanoate and histidine (His) had lower concentrations. A heat map of plasma metabolic profiles is shown in Fig. 3B.

Fig. 3 Metabolomic profiles in plasma collected from the patients with ovarian cancer (OC) and controls (C). (A) Volcano plot of metabolite concentrations (µmol/g). X-axis indicates the log2-fold change (FC) of the averaged values of (OC/C). Y-axis indicates the –log10(P-value) (Wilcoxon test corrected by FDR). Representative metabolites were shown in box plots. (B) Heatmap visualization.

Urine sample analyses quantified 140 metabolites, of which 10 metabolites showed significant differences between the two groups (Fig. 4A and B). Salivary sample analyses quantified 82 metabolites and revealed that 50 metabolites differed significantly between the two groups (Fig. 5A and B). In these samples, all significantly different metabolites showed high OC concentrations.

Fig. 4 Metabolic profiles in urine. (A) Volcano plot of metabolite concentrations (no unit). X-axis indicates the log2-fold change (FC) of the averaged values of (OC/C). Y-axis indicates the –log10(P-value) (Wilcoxon test corrected by FDR). Representative metabolites were shown in box plots. (B) Heatmap visualization. Urinary metabolite concentration was calculated by dividing the creatinine concentration of each sample.

Fig. 5 Metabolic profiles in saliva. (A) Volcano plot of metabolite concentrations (µmol/g). X-axis indicates the log2-fold change (FC) of the averaged values of (OC/C). Y-axis indicates the –log10(P-value) (Wilcoxon test corrected by FDR). Resentative metabolites were shown in box plots. (B) Heatmap visualization.

Metabolites consistently different among three biofluids and tissue samples

The number of metabolites showing significantly different concentrations between OT and NT samples and between OC and C plasma samples is shown in Fig. 6A. In totally, 12 metabolites were significantly different (P < 0.05) in both samples, and five metabolites were significantly different using an FDR-corrected P < 0.05. (Table S1). Two acetylated polyamines, –N-acetylasparate, betaine and His–were also included. Four of these metabolites were consistently elevated in the OT and OC groups (Figure S3).

Fig. 6 Metabolites consistently elevated in tissue and multiple biofluids. (A) The number of significantly different metabolites between plasma and tissues (FDR-corrected P-value < 0.05). (B) The number of significantly different metabolites in saliva, plasma, and urine samples (FDR-corrected P-value < 0.05). (C) ROC curves to discriminate OT from NT (tissue) and OC from C (biofluids). AUC, 95% confidential intervals, and P-values are described.

The number of metabolites showing significantly different concentrations between OC and C in the three types of biofluids is shown in Fig. 6B. N1,N12-diacetylspermine levels were consistently elevated in the biofluids. The discriminatory abilities of this metabolite for tissues (OT vs. NT) and biofluids (OC vs. C) is shown in Fig. 6C. The AUC value for the tissue sample was the highest at 0.950 (95% confidence interval [CI]: 0.889−1.000). The AUCs for plasma and urine were similar: 0.734 (95% CI: 0.612−0.857) for plasma and 0.755 (95% CI: 0.633−0.876) for urine. The saliva showed the lowest value; 0.681 (95% CI: 0.547−0.815).

Discussion

This study is the first study to systematically investigate metabolic changes between OT and NT in tissue samples, and OC and C in plasma, urine, and saliva samples. Most previous studies have used one or two biological samples for metabolic analysis to achieve early diagnosis and understand the underlying biological mechanisms of ovarian cancer.

Our metabolomic profiling of 24 paired OT and NT samples showed that the accumulation of lactate, an end product of glycolysis, and the reduction of intermediate metabolites in glycolysis, such as PEP and glycerate 3-phosphate (3PG) in OT (Figs. 1A and 2), indicating that the Warburg effect, a well-known characteristic of cancer cell energy metabolism, was observed in OC tissues. The glutamine and glutamic acid levels were significantly higher in the OT group than the NT group. Levels of metabolites in the latter half of the TCA cycle, such as succinate, fumarate, and malate, were significantly elevated in the OT group (Figs. 1A and 2). The activation of glycolysis and glutaminolysis in OC tissues is consistent with previous studies that performed metabolic analyses using various cancer tissues20–22. One-carbon metabolism, including that of choline, betaine, methionine, S-adenosylmethionine (SAM), and S-adenosylhomocysteine (SAH) was higher in the OT group (Figs. 1A and 2). The metabolites produced are made available for nucleotide biosynthesis, methylation, regulation of redox status, which contribute to cell proliferation, chemoresistance, and survival in OC23. In our paired tissue samples, metabolites associated with the urea cycle and polyamine pathway were elevated in the OT group compared to those in the NT group (Figs. 1A and 2). These results are consistent with that of a previous study which investigated metabolic alterations in unpaired normal ovarian and primary OC tissues22. The alterations in the urea cycle are also associated with cancer progression24. Notably, polyamines have been reported to be more abundant in high-grade serous carcinomas (HGSC) than in non-HGCS17, implying that the polyamine pathway may be involved in the aggressive phenotype of OC.

To identify the best biofluid reflecting metabolic dysregulation in OC tissues, we compared the metabolomic profiles of plasma, urine, and saliva between OC and C groups. The number of metabolites showing significantly different concentrations in three types of biofluids between the two groups was less than that between the OT and NT groups in the tissue samples (Figs. 3A and 4A, and 5). Our metabolic profiling demonstrated that plasma could be the best biofluid to reflect metabolic dysregulation in OC tissues. In totally, 12 metabolites showed consistently significant differences in both the plasma and tissue samples (Supplementary Table S1). Four metabolites, His, Leu, Met, and Trp, showed higher concentrations in OT but not in plasma samples, indicating that these metabolites might be actively taken up from the plasma into the tissues. N1,N12-diacetylspermine was consistently elevated in cancer tissues and the three types of biofluids (Figs. 1A and 6B). The discriminant abilities of this metabolite for tissues (OT from NT) and the biofluids (OC from C) were significant (Fig. 6C). Elevation of N1,N12-diacetylspermine, a polyamine metabolite, indicates that the polyamine pathway may play an essential role in OC metabolism. Elevated polyamine levels are involved in the initial stage of neoplastic transformation and tumor progression25,26. Previous studies have reported that plasma polyamines are useful for detecting early-stage OC9, and urinary polyamines can distinguish between benign and malignant ovarian tumors in both early and advanced stage13. Ornithine decarboxylase (ODC) is the first enzyme in the polyamine synthesis pathway in mammals and is transcriptionally regulated by MYC27,28. Integrated genome analysis has demonstrated that MYC is amplified in 30–40% of human ovarian tumors29, thereby linking the polyamine pathway and OC carcinogenesis via MYC. Moreover, the interaction between polyamine metabolism and other cancer-driving pathways, including the PTEN-PI3K-mTOR, WNT signaling and RAS pathways, suggests that the polyamine pathway is a potential therapeutic target30. Furthermore, in malignant gliomas and colon cancers, difluoromethlyornithine (DFMO), a specific inhibitor of ODC, has progressed to clinical trials31,32. Similarly, our results showed that the polyamine pathway is activated in OC, and further study is necessary to evaluate the specificity of this activation.

Nonetheless, this study had some potential limitations. The median age in the OC group was significantly higher than that in the control group, indicating that age may be a confounding variable in our analyses. The metabolomic profiles of tissue samples were clustered to separate NT and OT rather than the age (Figure S4). The age-mapped score plots of PCA also showed no apparent age-dependent age (Figure S5). The metabolomic profiles of the plasma sample also showed no clear age-dependent cluster (Figure S6). Nevertheless, age-matched studies are preferred to avoid histological and tumor burden biases. The relationship between the metabolomic profile and prognosis was also not analyzed because of the few cases of recurrence. More extensive samples are necessary for such analyses and rigorous validations.

In summary, our metabolomic profiling of tissues, plasma, urine, and saliva demonstrated that plasma is the best biofluid for reflecting metabolic changes in OC tissues. N1,N12-diacetylspermine, a component of the polyamine metabolomic pathway, was consistently elevated in tissues and three types of biofluids, implying that polyamine pathway may play an essential role in OC metabolism.

Materials and methods

Study subjects

This study was conducted according to the study protocol and was approved by the Ethics Committee of Yamagata University School of Medicine (2019 − 385). Written informed consent was obtained from each participant prior to participation in the study. Patients with OC and benign gynecological diseases were recruited from the Department of Obstetrics and Gynecology at Yamagata University Hospital between March 2020 and December 2021. None of the patients had received any prior treatment such as chemotherapy or radiotherapy. None of the patients had any history of malignancy.

Collection of tissues and biofluids

All patients with OC provided tumor and normal tissues and plasma, urine, and saliva samples. Patients with benign gynecological diseases included plasma, urine, and saliva samples. OC and normal tissues were collected during surgery. Pathologically confirmed to be cancer-free, the healthy ovary was used as normal tissues. Biofluid samples were collected from all participants between 06:00am–9:30am the day before surgery. The study participants had not eaten or drunk since the night before biofluid collection. After collection, these samples were immediately stored at − 80 °C.

Metabolomics analysis

Metabolomic analyses were conducted using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) and liquid chromatography triple quadrupole mass spectrometry (LC-QQQMS). CE-TOFMS was used to profile hydrophilic metabolites. LC-QQQMS was used for the highly sensitive quantification of polyamines. The parameters of analytical instruments were described for tissue samples20 and plasma, urine, and saliva33–35.

Sample processing for CE-TOFMS

The saliva sample (100 µl) was centrifuged through a 5-kDa-cutoff filter (Millipore, Bedford, MA, USA) at 9100 × g for at least 2.5 h at 4 °C. The filtrate (45 µl) was transferred to a 1.5-ml Eppendorf tube with 2 mM of internal standards 1 (methionine sulfone, 2-[N-morpholino]-ethanesulfonic acid [MES], D-camphol-10-sulfonic acid, sodium salt, 3-aminopyrrolidine, and trimesate), mixed by Voltex, and used for CE-TOFMS analysis.

The urine sample (20 µl) was mixed 80 µL methanol and 250 µM each of internal standards 1 and centrifuged through a 5-kDa cutoff filter (Millipore) at 9100 × g for at 30 min at 4 °C. The filtrate was used for the CE-TOFMS analysis.

Plasma sample (40 µL) was mixed with 360 µL methanol containing 20 µM each of internal standards 1. Deionized water (160 µL) and chloroform (400 µL) were added, and the solution was centrifuged at 10,000×g for 3 min at 4 °C. The upper aqueous layer was filtered through a 5-kDa cutoff filter (Millipore) at 9100×g for 180 min at 4 °C. The remaining solution was then centrifuged (960× g) for 3 h at 40 °C. Mill-Q water (40 µL) containing internal standards 2 (200 µM of 3-aminopyrrolidine and trimesate) was used for CE-TOFMS analysis.

Tissue samples (approximately 50 mg) were plunged into methanol (500 µl) containing internal standards and 20 M each of internal standard 1 and homogenized at 1500 rpm for 1 min using a Shake Master Neo (BMS, Tokyo, Japan). Chloroform (500 µl) and of Milli-Q water (200 µl) were added to of the homogenized solution (500 µl), and the mixed solution was centrifuged at 4600×g for 15 min at 4 °C. The upper aqueous layer (300 µl) was centrifugally filtered at 9100×g for 3.5 h at 4 °C through a 5-kDa cutoff filter (Millipore). The 150 µl filtrate was lyophilized and dissolved in 50 µl of Milli-Q water containing 200 µM of internal standard 2 for CE-TOFMS analysis.

Sample processing for LC-QQQMS

Either saliva (10 µl) or urine (10 µl) was mixed with methanol (90 µl) containing 149.6 mM ammonium hydroxide [1% (v/v) ammonia solution] and 0.9 µM internal standards 3 (d8-spermine, d8-spermidine, d6-N1-acetylspermidine, d3-N1-acetylspermine, d6-N1,N8-diacetylspermidine, d6-N1,N12-diacetylspermine, and 1,6-diaminohexane). After centrifugation at 15,780×g for 10 min at 4 °C, the supernatant was transferred to a fresh tube and vacuum dried. The sample was reconstituted with 90% (v/v) methanol (10 µl) and water (30 µl) and then vortexed and centrifuged at 15,780 × g for 10 min at 4 °C. The 38 10 µl of supernatant was then injected into the LC-QQQMS. The urine sample was diluted 5000 fold and processed in the manner described above for the creatinine quantification.

Plasma (30 µl) was mixed with methanol (270 µl) containing 149.6 mM ammonium hydroxide [1% (v/v) ammonia solution] and internal standard 1 (0.2 µM). After centrifugation at 15,780 × g for 10 min at 4 °C, the supernatant was transferred to a fresh tube and vacuum dried. The sample was reconstituted with 90% methanol (10 µl) and water (20 µl) and then vortexed and centrifuged at 15,780 × g for 1 min at 4 °C, and supernatant (28 µl) was then injected into the LC-QQQMS.

Tissue samples (approximately 50 mg) were plunged into methanol (500 µl) containing internal standards and 20 M each of internal standard 1 and homogenized at 1500 rpm for 1 min using a Shake Master Neo (BMS). Homogenized solution (50 µl) was mixed with methanol (100 µl) containing 149.6 mM ammonium hydroxide [1% (v/v) ammonia solution] and 0.75 µM internal standard 3, and the mixed solution was centrifuged at 4600×g for 15 min at 4 °C. The supernatant was transferred to a fresh tube and centrifuged at 9100×g for 1 h at 40 °C. The sample was reconstituted with 90% (v/v) methanol (20 µl) and water (60 µl) and then vortexed and centrifuged at 15,780 × g for 1 min at 4 °C. The sample (75 µl) was transferred to a vial for LC-QQQMS analysis.

Data processing

The raw metabolomic data were processed using MasterHands (ver. 2.19.0.1, Keio University, Yamagata, Japan) to produce a data matrix (sample × metabolite) including absolute concentrations36. Briefly, migration time (MT) of each metabolite peak was corrected based on internal standards. The metabolites were identified based on the corrected MT and m/z values by matching those of the standard compounds. The peak area of each metabolite was integrated and divided by that of one of the internal standards to obtain the relative area. The ratio of the relative areas of the metabolites in a sample to the standard mixture was used to calculate the absolute metabolite concentrations in the samples37. The absolute concentration of each metabolite for saliva and plasma was used for subsequent analyses. The concentration of each metabolite was divided by creatinine concentrations for each urine sample. The metabolite concentration was divided by each tissue sample’s wet weight.

The quantitative and nominal scales of the subject characteristics were evaluated using the Mann-Whitney and Chi-square tests. Metabolite concentrations were evaluated using the Wilcoxon matched-pair test for pairs (tissue), Mann-Whitney tests, and non-paireds samples (plasma, urine, and saliva). P-values were corrected using the false discovery rate (FDR) for multiple independent tests.

The heatmap shows the relatively high (red) and low (blue) concentrations of each metabolite. Normalization by sum, log transformation, and auto-scaling (Z-score) was used for data processing. The elucidation distance was used for clustering. MetaboAnalyst (v. 5.0 and v 6.0) was used to visualize volcano plots and heatmaps and conduct principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), and pathway analysis38. GraphPad Prism (v. 9.2.0, GraphPad Software, San Diego, CA, USA) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) were used for all other analyses.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1.

Supplementary Material 2.

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing.

Author contributions

T.O., M.S., M.S., and S.N. concieved this study. T.O., M.S., and S.N. initiated and managed the collaboration. T.O., Y.I., S.H., Y.O., H.S., and M.S. collected tissues and biofluid samples. T.O. and M.S. wrote the main manuscript text and prepared Table 1; Figs. 1, 2, 3, 4, 5 and 6 and Supplementary Information File. T.O. wrote the first draft of the manuscript. All authors reviewed the manuscript and agreed with the submission.

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

Masahiro Sugimoto received annual value of remuneration from Saliva Tech Co. Ldt. and Human Metabolome Technologies Inc. Masahiro Sugimoto and Makoto Sunamura received annual profit from share from Saliva Tech Co. Ldt. The other authors declare no conflict of interest.

Ethical approval

The study protocol was approved by the Ethics Committee of Yamagata University School of Medicine (2019 − 385). All informed consent was obtained from each participant prior to participation in the study.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Hanahan D Weinberg RA Hallmarks of cancer: The next generation Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144(5), 646–674. 10.1016/j.cell.2011.02.013 (2011).21376230 10.1016/j.cell.2011.02.013
2. Benjamin DI Cravatt BF Nomura DK Global profiling strategies for mapping dysregulated metabolic pathways in cancer Cell Metab. 2012 16 5 565 577 10.1016/j.cmet.2012.09.013 23063552
Benjamin, D. I., Cravatt, B. F. & Nomura, D. K. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab. 16(5), 565–577. 10.1016/j.cmet.2012.09.013 (2012).23063552 10.1016/j.cmet.2012.09.013
3. Azad RK Shulaev V Metabolomics technology and bioinformatics for precision medicine Brief. Bioinform 2019 20 6 1957 1971 10.1093/bib/bbx170 29304189
Azad, R. K. & Shulaev, V. Metabolomics technology and bioinformatics for precision medicine. Brief. Bioinform. 20(6), 1957–1971. 10.1093/bib/bbx170 (2019). PMID: 29304189; PMCID: PMC6954408.29304189 10.1093/bib/bbx170
4. Jacob M Lopata AL Dasouki M Abdel Rahman AM Metabolomics toward personalized medicine Mass Spectrom Rev. 2019 38 3 221 238 10.1002/mas.21548 29073341
Jacob, M., Lopata, A. L., Dasouki, M. & Abdel Rahman, A. M. Metabolomics toward personalized medicine. Mass Spectrom Rev. 38(3), 221–238. 10.1002/mas.21548 (2019).29073341 10.1002/mas.21548
5. Shulaev V Metabolomics technology and bioinformatics Brief. Bioinform. 2006 7 2 128 139 10.1093/bib/bbl012 16772266
Shulaev, V. Metabolomics technology and bioinformatics. Brief. Bioinform. 7(2), 128–139. 10.1093/bib/bbl012 (2006).16772266 10.1093/bib/bbl012
6. Halket JM Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS J. Exp. Bot. 2005 56 410 219 243 10.1093/jxb/eri069 15618298
Halket, J. M. et al. Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. J. Exp. Bot. 56(410), 219–243. 10.1093/jxb/eri069 (2005). Epub 2004 Dec 23. PMID: 15618298.15618298 10.1093/jxb/eri069
7. The Surveillance. Epidemiology, and End Results (SEER) Program. https://seer.cancer.gov/statfacts/html/ovary.html (2023-05-29).
8. Henderson JT Webber EM Sawaya GF Screening for ovarian cancer: Updated evidence report and systematic review for the US preventive services task force JAMA. 2018 319 6 595 606 10.1001/jama.2017.21421 29450530
Henderson, J. T., Webber, E. M. & Sawaya, G. F. Screening for ovarian cancer: Updated evidence report and systematic review for the US preventive services task force. JAMA. 319(6), 595–606. 10.1001/jama.2017.21421 (2018).29450530 10.1001/jama.2017.21421
9. Fahrmann JF A MYC-Driven plasma polyamine signature for early detection of Ovarian Cancer Cancers (Basel) 2021 13 4 913 10.3390/cancers13040913 33671595
Fahrmann, J. F. et al. A MYC-Driven plasma polyamine signature for early detection of Ovarian Cancer. Cancers (Basel). 13(4), 913. 10.3390/cancers13040913 (2021). PMID: 33671595; PMCID: PMC7927060.33671595 10.3390/cancers13040913
10. Ke, C. et al. Large-scale profiling of metabolic dysregulation in ovarian cancer. Int J Cancer. ;136(3):516 – 26. doi: 10.1002/ijc.29010. Epub 2014 Jun 17. PMID: 24895217. (2015).
11. Bachmayr-Heyda A Integrative systemic and local metabolomics with impact on survival in high-grade serous ovarian cancer Clin. Cancer Res. 2017 23 8 2081 2092 10.1158/1078-0432.CCR-16-1647 27797973
Bachmayr-Heyda, A. et al. Integrative systemic and local metabolomics with impact on survival in high-grade serous ovarian cancer. Clin. Cancer Res. 23(8), 2081–2092. 10.1158/1078-0432.CCR-16-1647 (2017).27797973 10.1158/1078-0432.CCR-16-1647
12. Buas MF Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors Gynecol. Oncol. 2016 140 1 138 144 10.1016/j.ygyno.2015.10.021 26521694
Buas, M. F. et al. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol. Oncol. 140(1), 138–144. 10.1016/j.ygyno.2015.10.021 (2016). Epub 2015 Oct 30. PMID: 26521694; PMCID: PMC5310763.26521694 10.1016/j.ygyno.2015.10.021
13. Niemi RJ Urinary polyamines as biomarkers for ovarian cancer Int. J. Gynecol. Cancer. 2017 27 7 1360 1366 10.1097/IGC.0000000000001031 28604456
Niemi, R. J. et al. Urinary polyamines as biomarkers for ovarian cancer. Int. J. Gynecol. Cancer. 27(7), 1360–1366. 10.1097/IGC.0000000000001031 (2017).28604456 10.1097/IGC.0000000000001031
14. Slupsky CM Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers Clin. Cancer Res. 2010 16 23 5835 5841 10.1158/1078-0432.CCR-10-1434 20956617
Slupsky, C. M. et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 16(23), 5835–5841. 10.1158/1078-0432.CCR-10-1434 (2010). Epub 2010 Oct 18. PMID: 20956617.20956617 10.1158/1078-0432.CCR-10-1434
15. Denkert C Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors Cancer Res. 2006 66 10795 10804 10.1158/0008-5472.CAN-06-0755 17108116
Denkert, C. et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 66, 10795–10804. 10.1158/0008-5472.CAN-06-0755 (2006).17108116 10.1158/0008-5472.CAN-06-0755
16. Fong MY McDunn J Kakar SS Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer PLoS One 2011 6 1 12 10.1371/journal.pone.0019963
Fong, M. Y., McDunn, J. & Kakar, S. S. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One. 6, 1–12. 10.1371/journal.pone.0019963 (2011).10.1371/journal.pone.0019963
17. Yoshida K Metabolome analysis reveals a diversity of cancer tissues in advanced epithelial ovarian cancer Cancer Cell. Int. 2021 21 1 314 10.1186/s12935-021-02014-7 34134729
Yoshida, K. et al. Metabolome analysis reveals a diversity of cancer tissues in advanced epithelial ovarian cancer. Cancer Cell. Int. 21(1), 314. 10.1186/s12935-021-02014-7 (2021). PMID: 34134729; PMCID: PMC8207638.34134729 10.1186/s12935-021-02014-7
18. Murata T Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination Breast Cancer Res. Treat. 2019 177 3 591 601 10.1007/s10549-019-05330-9 31286302
Murata, T. et al. Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination. Breast Cancer Res. Treat. 177(3), 591–601. 10.1007/s10549-019-05330-9 (2019). Epub 2019 Jul 8. PMID: 31286302.31286302 10.1007/s10549-019-05330-9
19. Asai Y Elevated polyamines in saliva of pancreatic cancer Cancers (Basel) 2018 10 2 43 10.3390/cancers10020043 29401744
Asai, Y. et al. Elevated polyamines in saliva of pancreatic cancer. Cancers (Basel) 10(2), 43. 10.3390/cancers10020043 (2018).29401744 10.3390/cancers10020043
20. Ishikawa S Identification of salivary metabolomic biomarkers for oral cancer screening Sci. Rep. 2016 6 31520 10.1038/srep31520 27539254
Ishikawa, S. et al. Identification of salivary metabolomic biomarkers for oral cancer screening. Sci. Rep. 6, 31520. 10.1038/srep31520 (2016). PMID: 27539254; PMCID: PMC4990923.27539254 10.1038/srep31520
21. Satoh K Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC Proc. Natl. Acad. Sci. USA 2017 114 37 E7697 E7706 10.1073/pnas.1710366114 28847964
Satoh, K. et al. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc. Natl. Acad. Sci. USA 114(37), E7697–E7706. 10.1073/pnas.1710366114 (2017).28847964 10.1073/pnas.1710366114
22. Fong MY McDunn J Kakar SS Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer PLoS One 2011 6 5 e19963 10.1371/journal.pone.0019963 21625518
Fong, M. Y., McDunn, J. & Kakar, S. S. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One. 6(5), e19963. 10.1371/journal.pone.0019963 (2011). Epub 2011 May 19. PMID: 21625518; PMCID: PMC3098284.21625518 10.1371/journal.pone.0019963
23. Rizzo A One-carbon metabolism: Biological players in epithelial ovarian cancer Int. J. Mol. Sci. 2018 19 7 2092 10.3390/ijms19072092 30029471
Rizzo, A. et al. One-carbon metabolism: Biological players in epithelial ovarian cancer. Int. J. Mol. Sci. 19(7), 2092. 10.3390/ijms19072092 (2018).30029471 10.3390/ijms19072092
24. Keshet R Szlosarek P Carracedo A Erez A Rewiring urea cycle metabolism in cancer to support anabolism Nat Rev Cancer. 2018 18 10 634 645 10.1038/s41568-018-0054-z 30194362
Keshet, R., Szlosarek, P., Carracedo, A. & Erez, A. Rewiring urea cycle metabolism in cancer to support anabolism. Nat Rev Cancer. 18(10), 634–645. 10.1038/s41568-018-0054-z (2018).30194362 10.1038/s41568-018-0054-z
25. Murray-Stewart TR Woster PM Casero RA Jr Targeting polyamine metabolism for cancer therapy and prevention Biochem. J. 2016 473 19 2937 2953 10.1042/BCJ20160383 27679855
Murray-Stewart, T. R., Woster, P. M. & Casero, R. A. Jr Targeting polyamine metabolism for cancer therapy and prevention. Biochem. J. 473(19), 2937–2953. 10.1042/BCJ20160383 (2016). PMID: 27679855; PMCID: PMC5711482.27679855 10.1042/BCJ20160383
26. Gerner EW Meyskens FL Jr Polyamines and cancer: old molecules, new understanding Nat Rev Cancer. 2004 4 10 781 92 10.1038/nrc1454 15510159
Gerner, E. W. & Meyskens, F. L. Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 4(10), 781–92. 10.1038/nrc1454 (2004).15510159 10.1038/nrc1454
27. Fahrmann JF Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer J. Natl. Cancer Inst. 2020 112 6 607 616 10.1093/jnci/djz182 31503278
Fahrmann, J. F. et al. Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer. J. Natl. Cancer Inst. 112(6), 607–616. 10.1093/jnci/djz182 (2020).31503278 10.1093/jnci/djz182
28. Bachmann AS Geerts D Polyamine synthesis as a target of MYC oncogenes J. Biol. Chem. 2018 293 18757 18769 10.1074/jbc.TM118.003336 30404920
Bachmann, A. S. & Geerts, D. Polyamine synthesis as a target of MYC oncogenes. J. Biol. Chem. 293, 18757–18769 (2018).30404920 10.1074/jbc.TM118.003336
29. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 474(7353):609 – 15. (2011). 10.1038/nature10166. Erratum in: Nature. 2012;490(7419):298.
30. Casero RA Jr Murray Stewart T Pegg AE Polyamine metabolism and cancer: treatments, challenges and opportunities Nat. Rev. Cancer 2018 18 11 681 695 10.1038/s41568-018-0050-3 30181570
Casero, R. A. Jr, Murray Stewart, T. & Pegg, A. E. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat. Rev. Cancer. 18(11), 681–695. 10.1038/s41568-018-0050-3 (2018). PMID: 30181570; PMCID: PMC6487480.30181570 10.1038/s41568-018-0050-3
31. Levin VA Ictech SE Hess KR Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas CNS Oncol. 2018 7 2 CNS16 10.2217/cns-2017-0031 29378419
Levin, V. A., Ictech, S. E. & Hess, K. R. Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 7(2), CNS16. 10.2217/cns-2017-0031 (2018).29378419 10.2217/cns-2017-0031
32. Raj KP Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas Br. J. Cancer 2013 108 3 512 518 10.1038/bjc.2013.15 23340449
Raj, K. P. et al. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br. J. Cancer. 108(3), 512–518. 10.1038/bjc.2013.15 (2013). Epub 2013 Jan 22. PMID: 23340449; PMCID: PMC3593561.23340449 10.1038/bjc.2013.15
33. Iwamoto H Metabolomic profiling of plasma, urine, and saliva of kidney transplantation recipients Int. J. Mol. Sci. 2022 23 22 13938 10.3390/ijms232213938 36430414
Iwamoto, H. et al. Metabolomic profiling of plasma, urine, and saliva of kidney transplantation recipients. Int. J. Mol. Sci. 23(22), 13938. 10.3390/ijms232213938 (2022). PMID: 36430414; PMCID: PMC9695205.36430414 10.3390/ijms232213938
34. Sugimoto M Aizawa Y Metabolomics analysis of blood, urine, and saliva samples based on capillary electrophoresis-mass spectrometry Methods Mol Biol. 2023 2571 83 94 10.1007/978-1-0716-2699-3_8 36152152
Sugimoto, M. & Aizawa, Y. Metabolomics analysis of blood, urine, and saliva samples based on capillary electrophoresis-mass spectrometry. Methods Mol Biol. 2571, 83–94. 10.1007/978-1-0716-2699-3_8 (2023).36152152 10.1007/978-1-0716-2699-3_8
35. Tomita A Effect of storage conditions on salivary polyamines quantified via liquid chromatography-mass spectrometry Sci. Rep. 2018 8 1 12075 10.1038/s41598-018-30482-x 30104641
Tomita, A. et al. Effect of storage conditions on salivary polyamines quantified via liquid chromatography-mass spectrometry. Sci. Rep. 8(1), 12075. 10.1038/s41598-018-30482-x (2018). PMID: 30104641; PMCID: PMC6089938.30104641 10.1038/s41598-018-30482-x
36. Sugimoto M Wong DT Hirayama A Soga T Tomita M Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles Metabolomics 2010 6 1 78 95 10.1007/s11306-009-0178-y 20300169
Sugimoto, M., Wong, D. T., Hirayama, A., Soga, T. & Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 6(1), 78–95. 10.1007/s11306-009-0178-y (2010). Epub 2009 Sep 10. PMID: 20300169; PMCID: PMC2818837.20300169 10.1007/s11306-009-0178-y
37. Sugimoto M Aizawa Y Tomita A Data processing and analysis in liquid chromatography-mass spectrometry-based targeted metabolomics Methods Mol Biol. 2023 2571 241 255 10.1007/978-1-0716-2699-3_21 36152165
Sugimoto, M., Aizawa, Y. & Tomita, A. Data processing and analysis in liquid chromatography-mass spectrometry-based targeted metabolomics. Methods Mol Biol. 2571, 241–255. 10.1007/978-1-0716-2699-3_21 (2023).36152165 10.1007/978-1-0716-2699-3_21
38. Pang Z MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights Nucleic Acids Res. 2021 49 W1 W388 W396 10.1093/nar/gkab382 34019663
Pang, Z. et al. MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 49(W1), W388–W396. 10.1093/nar/gkab382 (2021).34019663 10.1093/nar/gkab382
